Is Hyaluronic Acid Filler for Tear Troughs Safe?

Hyaluronic acid (HA) filler injection for tear trough correction is generally considered safe when performed by a qualified, experienced clinician using appropriate techniques and FDA-approved or CE-marked products. The tear trough—a natural depression extending from the inner canthus downward and laterally along the infraorbital rim—is a complex anatomical area with thin skin, prominent vasculature, and proximity to the orbital septum and fat compartments. Complications, though uncommon, can occur and include transient swelling, bruising, and mild erythema; these typically resolve within days to a week.

More serious but rare adverse events may include vascular compromise—such as retrograde embolization leading to skin necrosis or, in extreme cases, vision loss—particularly if filler is inadvertently injected into the angular or dorsal nasal artery. To mitigate risk, practitioners employ strategies such as using blunt-tipped microcannulas, applying gentle pressure during injection, aspirating before deposition, and avoiding high-volume or high-pressure bolus injections. Patient selection is equally critical: individuals with severe volume loss, significant skin laxity, or active periorbital inflammation may be poor candidates and could benefit more from surgical options like fat repositioning or transconjunctival blepharoplasty.

Long-term safety data support HA fillers’ favorable profile in this region due to their biodegradability and reversibility with hyaluronidase—an enzyme that rapidly degrades the product in cases of overcorrection, asymmetry, or vascular compromise. Nevertheless, outcomes are highly operator-dependent, and evidence-based consensus guidelines recommend limiting total injected volume to 0.5–1.0 mL per side and prioritizing conservative correction over aggressive augmentation.